MBX Biosciences announces key milestones for 2026 including Phase 2 trial data and new obesity candidates nominations.
The company's precision peptide therapies show promise for treating endocrine and metabolic disorders.
Strong cash position with approximately $373.7 million as of December 31, 2025, supporting operations into 2029.
Successful Phase 2 Trial
Avail trial of once-weekly canvuparatide for hypoparathyroidism achieved primary endpoint with high responder rates.
Expanding Obesity Pipeline
Progress on MBX 4291 and plans for new obesity candidates nominations in 2026.
Long-acting Imapextide Progress
Updates on Phase 2a trial results and patient preferences for once-weekly injections.
Financial Strength
Preliminary unaudited cash reserves of $373.7 million to support operations into 2029.
- Successful Phase 2 trial sets stage for pivotal Phase 3 trial for hypoparathyroidism treatment.
- Expansion of obesity pipeline with potential once-monthly dosing candidates expected to address patient needs.
- Positive feedback on long-acting Imapextide's trial results and patient preferences highlight market potential.
- Strong financial position provides stability for long-term pipeline growth and strategic investments.
MBX Biosciences' robust pipeline progress and financial stability position the company for a catalyst-rich 2026.